Agilon Health, Inc. · NYSE:AGL
Agilon Health — Investor Day (March 2023)
71 slides from Agilon Health's investor day presentation, Mar 30, 2023
Slide 1: Welcome to 2023 Investor Day
Welcome to 2023 Investor Day. Matthew Gillmor Vice President, Investor Relations 03.30.2023 Copyright © 2023 agilon health
Slide 2: Disclaimers and Forward-Looking Statements
Disclaimers and Forward-Looking Statements FORWARD-LOOKING STATEMENTS AND OTHER INFORMATION Statements in this presentation that are not historical factual statements are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the
Slide 3: Investor Day Agenda
Investor Day Agenda Topic / Focus Speakers Welcome and Agenda Matthew Gillmor, Vice President of Investor Relations Introduction and Overview Steve Sell, Chief Executive Officer Dr. Ben Kornitzer, Chief Medical Officer Clinical Quality Performance Heidi Hittner, Chief Experience Officer Physician Pa
Slide 4: Introduction & Overview
Introduction & Overview Steven Sell Chief Executive Officer Copyright © 2023 agilon health
Slide 5: Key Takeaways
Key Takeaways Solving a Fundamental Performance Higher Confidence and Problem for Primary Creating a Visibility in Long-term Care Powerful Flywheel Outlook Copyright © 2023 agilon health 5
Slide 6: Primary Care Economics and Capacity Are Getting Worse
Primary Care Economics and Capacity Are Getting Worse Challenged Primary Care PCP Economics 20%+ Decline Capacity is Strained in PCP Economics 50% for Medicare 100% ~10–20% % Change Since 2001 30% Projected 50% Shortage by 2030 10% 0% (10%) 2001 2006 2011 2016 2022 2022 2024 2026 2028 2030 Physician
Slide 7: While Senior Patient Outcomes Are Poor and Highly Variable
While Senior Patient Outcomes Are Poor and Highly Variable Variation in Preventative Services Variation in Cost & Utilization <19 19 28 35 44+ AWV Completion Rate (%) ~ 2X Variation in Medicare spending across regions Uncoordinated ~ 3X & Fragmented Variation in Medicare inpatient days across region
Slide 8: System is Asking More of the Primary Care Doctor
System is Asking More of the Primary Care Doctor Growing Senior Population Increasing Medicare Population 2020–2030 Focus on Value 75M 100% 62M CMS target for Medicare 2020 2030 beneficiaries in total cost models by 2030 Copyright © 2023 agilon health 8
Slide 9: We Are Solving That Problem & Creating a Better Health Care System
We Are Solving That Problem & Creating a Better Health Care System Total Care Model Driving Consistency Patient Access Quality Utilization STARs Performance by Market Class Readmissions 17.4% 12.4% 79% 4.5 Class of 2018 Class of 2019 Readmission Rate Class of 2020 4.3 Class of 2021 Hospital Admissio
Slide 10: Better Performance Drives More Surplus to Reinvest in Practices
Better Performance Drives More Surplus to Reinvest in Practices $550M $250M Projected 2023 Projected 2023 medical margin reinvestment to partners/ local primary care Note: Reinvestment based on management’s guidance for 2023 Copyright © 2023 agilon health 10
Slide 11: Performance is Driving Growth
Performance is Driving Growth Class of 2024 Now Expected to Add Over 100K New MA Members, Driving Total MA Member Additions to 145K in 2024 PCPs on Platform Markets (live and implementing) 2,700+ 32 2,200+ ~60% 25 Invest More CAGR 1,600+ 17 1,190 PCPs Join in Care 980 11 785 agilon Delivery 8 Networ
Slide 12: Growth Drives Scale
Growth Drives Scale Our Platform is the Solution for PCPs in VBC agilon Network: 32 Markets in 14 States Minnesota • Twin Cities Michigan • Traverse City Ohio • Columbus Maine • Portland Competitive Moat: • Lewiston • Grand Rapids • Detroit • Akron • Zanesville • Bangor Local and National VBC • Dayt
Slide 13: Higher Confidence and Visibility in Long-term Outlook
Higher Confidence and Visibility in Long-term Outlook Visibility and Confidence in Value Drivers Has Strengthened Putting More Accelerating Continuing Operating Members on the Performance Margin Leverage Platform, Earlier of Newer Progression Markets for Mature Markets Copyright © 2023 agilon health
Slide 14: Pushing Our Leadership Position
Pushing Our Leadership Position Delivering Scaled, Technology & Data: Using Capital to Help National Clinical mphrX Acquisition Partners Improve Solutions Outcomes Copyright © 2023 agilon health 14
Slide 15: Clinical Quality Performance
Clinical Quality Performance Heidi Hittner, Chief Experience Officer Dr. Ben Kornitzer, Chief Medical Officer Copyright © 2023 agilon health
Slide 16: Key Themes
Key Themes Better Outcomes and Demonstrated Scalable Capability Experience for Patients Consistency in Our New Across Markets and Providers Primary Care Model and Conditions Copyright © 2023 agilon health 16
Slide 17: Patients with Multiple Chronic Conditions Account for a Disproportionate Share of Expenditures
Patients with Multiple Chronic Conditions Account for a Disproportionate Share of Expenditures Distribution of Spend by Number of Chronic Conditions Number of Chronic Per Capita Conditions, % Spending; PMPY,1 $ 6+ Conditions 17% 50+% of spend 53% $29,004 is driven by patients 4 to 5 Conditions 21% w
Slide 18: Scaling Quality Outcomes Across Our Network
Scaling Quality Outcomes Across Our Network agilon Outperforming MA on Key Star Measures Gap Closure Improving Faster than MA Breast Cancer 3 Cancer Screening 5 88 87 Screening 87 86 86 Colorectal Cancer 3 86 % Gap Closure Rate Screening 5 85 84 agilon Statin Therapy 3 83 Cardiovascular 83 Disease 4
Slide 19: Process Driving Standardization in Care Model
Goal is to Have a Process that Drives Greater Standardization in Care Model and Enables our Partnerships to Drive Consistent Outcome Process Target 1 % of total patient population identified Steps in Condition specific the Funnel 2 % of identified patients outreached 100% 3 % of identified patients
Slide 20: agilon Platform Enables PCPs to Extend Reach Beyond Their Office
agilon Platform Enables PCPs to Extend Reach Beyond the Four Walls of their Office Pharmacist Care Manager Lower Performing PCPs in 2020 100% 2020 HbA1C Gap Closure Rate (%) Lost to Change in 90% Follow-Up Health Plan 80% 70% 60% 50% 40% 30% 20% 10% Homebound 0% Patients Cardiologist 0% 20% 40% 60%
Slide 21: Improving Diabetic Eye Screening Rates and A1c Control
agilon is Improving Diabetic Eye Screening Rates and A1c Control Faster Than Both FFS and MA Improving Diabetes Eye Exam Screening Rates and Diabetes A1c Control Eye Exam for Patients with Diabetes Hemoglobin A1c Control for Patients with Diabetes 90% 90% 88% agilon % agilon 85% improvement in eye e
Slide 22: Quality Improvements Translate into Lower Utilization and Cost of Care
Quality Improvements Translate into Lower Utilization and Cost of Care Acute Inpatient Admits per Thousand Total Medical Expense PMPM Uncontrolled 200 ’20 &’21 183 Patients with consistent 157 $698 HbA1c control 153 150 cost 19% less Controlled than patients who are not Controlled ’20 &’21 agilon pa
Slide 23: Scalable Capability Applied Across Markets and Conditions
Scalable Capability is Being Applied Across Markets and Conditions to Improve Quality Palliative Care Renal Care Cardiology Care 12% reduction 25% reduction 25% reduction 17% reduction 15% reduction 25% reduction PMPM PMPM PMPM Spend Spend Spend Bottom Top Quartile New Care Bottom Top Quartile New C
Slide 24: Physician Panel
Physician Panel Dr. Kevin Spencer, Chief Clinical Partner Dr. John Notaro, Buffalo Medical Group Dr. Brady Steineck, Community Health, Akron OH Dr. Liam Fry, Premier Family Physicians (AGS Austin) Copyright © 2023 agilon health
Slide 25: agilon Platform
agilon Platform Ben Shaker, Chief Markets Officer Dr. Patrick Goggin Physician Group of Southeastern Ohio Girish Venkatachaliah Chief Technology Officer Copyright © 2023 agilon health
Slide 26: Key Takeaways
Key Takeaways Built to Drive Consistent Model is Transforming Our Platform is Getting Outcome at Scale Delivery of Patient Care Smarter as We Scale Copyright © 2023 agilon health 26
Slide 27: Model Built for Rapid Scale
Model Built for Rapid Scale Copyright © 2023 agilon health 27
Slide 28: Highly Variable Patient Access in Baseline Years
Consistent Highly Outcomes Variable Across Patient Our Access in Network Baseline Years PCP PCPPerformance: Performance:Year 20220 100% Avg: 92% 90% Avg: 79% Assessment of Chronic Conditions 80% 70% 60% 50% 40% 30% 20% 10% Avg: 57% Avg: 82% 0% 0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100% Valuable Vis
Slide 29: Care Quality Exceeds National Benchmarks
Care Quality Exceeds National Benchmarks PCP Performance: 2022 100% 90% Avg: 82% 80% National MA Benchmark Breast Cancer Screening 70% 60% 50% 40% 30% 20% 10% Avg: 81% 0% 0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100% Colorectal Cancer Screening Note: Reflects established partner markets with complete
Slide 30: Common Model Deployed Across Local Markets
Common Model Deployed Across Local Markets Consistent Comprehensive Insight into Enhanced Operating Structure Data Access Patient Population Clinical Resources Common Operating System Copyright © 2023 agilon health 30
Slide 31: Deep Dive: Physician Group of Southeastern Ohio (PGSEO)
Deep Dive: Physician Group of Southeastern Ohio (PGSEO) Independent Multi-TIN IPA model in rural service area spanning 3 counties across SE Ohio From To 25 physicians in 17 locations 37 physicians in 21 locations High fragmentation and minimal United by a shared identity, purpose, structure, central
Slide 32: Partnership Drove Improved Patient Access
Partnership Drove Improved Patient Access 2020 PCP Performance: 2022 100% 90% Avg: 95% Assessment of Chronic Conditions 80% 70% Avg: 79% 60% 50% 40% 30% 20% 10% Avg: 60% Avg: 84% 0% 0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100% Valuable Visits Note: Physician Group of Southeastern Ohio (PGSEO) perform
Slide 33: Partnership Drove Improved Care Quality
Partnership Drove Improved Care Quality PCP Performance: 2022 2020 100% 90% Avg: 83% 80% Breast Cancer Screening 70% Avg: 78% 60% 50% 40% 30% 20% 10% Avg: 55% Avg: 80% 0% 0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100% Colorectal Cancer Screening Note: Physician Group of Southeastern Ohio (PGSEO) perfor
Slide 34: Learning About High-Risk Patients at Point of Care
We’ve Learned Valuable Information About Our High-Risk Patients Right at Point of Care Agnes • Hypertension, dyslipidemia, Before essential tremor agilon • Lisinopril, amlodipine, propranolol • Last seen in office 9 months ago • BNP 1700 in 3/18/23 lab data • Chronic heart failure on claim by Cardio
Slide 35: Proactively Developing Strategies for High-Risk Patients
We Proactively Develop Strategies for Our High-Risk Patients Before They Walk in Our Doors Valerie • Diabetes, depression, Before tobacco dependence agilon • Sitagliptin, atorvastatin, sertraline • Last seen in office 6 months ago • Ejection fraction of 45% in Cardiology report on 12/2/22 • Payor al
Slide 36: Care Management Team Supports Patients During an Acute Event
Our Care Management Team Jumps into Action to Support Patients During an Acute Event George • Hypertension, diabetes, chronic kidney disease Before agilon • Lisinopril, basaglar, glimepiride • Missed scheduled appointment 2 months ago Alert! George is admitted to hospital Learns from Inpatient Team:
Slide 37: Our Technology Platform Enhances Access to Essential Clinical Data
Our Technology Platform Enhances Access to Essential Clinical Data Partner 660+ Physician Offices BNP 1700 in lab data Chronic heart failure on claim by Cardiology Associates 170+ Versions of EMRs Carotid stenosis in Neurology consultation note Ejection fraction of 45% in 130+ Health Plan Sources Ca
Slide 38: We Use AI to Learn Who Has Higher Acuity Needs
We Use AI to Learn Who Has Higher Acuity Needs Copyright © 2023 agilon health 38
Slide 39: Investment in Our Platform Opens Access to More Data
Investment in Our Platform Opens Access to More Data, Faster than Ever Before Enterprise FHIR® Platform for Value-based care Acquired 3/1/23 Copyright © 2023 agilon health 39
Slide 40: Key Takeaways
Key Takeaways Built to Drive Consistent Model is Transforming Our Platform is Getting Outcome at Scale Delivery of Patient Care Smarter as We Scale Copyright © 2023 agilon health 40
Slide 41: Growth Outlook
Growth Outlook Veeral Desai Chief Strategy and Development Officer Copyright © 2023 agilon health
Slide 42: Key Takeaways
Key Takeaways Inflection in Growth TAM Has Expanded and Early Lifecycle Growth is Happening is More Accessible Enhances Long-term Membership Visibility Copyright © 2023 agilon health 42
Slide 43: Macro Factors Supporting Inflection in Demand
Macro Factors Supporting Inflection in Demand Challenged PCP Economics 20%+ Decline in PCP Economics for Medicare 50% Increasing PCP Burnout % Change Since 2001 30% 59% 10% 47% (10%) 2001 2006 2011 2016 2022 Physician Reimbursement Practice Costs Growing Senior Population 75M 2018 2022 62M 2020 2030
Slide 44: Requires Scalable Solution for Existing PCP Capacity
Requires Scalable Solution for Existing PCP Capacity Only a small fraction Scaled solution of PCPs are in full risk uniquely focused on relationships today existing PCP capacity ~200k Adult PCPs Nationally Copyright © 2023 agilon health 44
Slide 45: agilon Partners' Performance Further Accelerating Adoption
agilon Partners’ Performance Further Accelerating Adoption Diverse Physician Organizations Now Have Direct Analogs within agilon Network Market Prospective Markets / Partners Feature Partner Example in Network Market 500k – 1.0M 4 Markets Population Group Type Type Primary Care 12 Partners Key Marke
Slide 46: Network Effect Accelerating Expansion
Network Effect Accelerating Expansion Minnesota Maine Michigan Ohio • Portland Development of New Hubs • Twin Cities • Traverse City • Columbus • Lewiston Key Source of Future Growth • Grand Rapids • Akron • Bangor • Detroit • Toledo • Zanesville New York Markets added Class of • Dayton • Syracuse 2
Slide 47: Platform Adoption is Inflecting
Platform Adoption is Inflecting New Partner Adds Accelerating Against a Backdrop of Increasing Sales Efficiency >$5.5B >100K in the class of 2024 550k $2.7B 405k 270k 186k 131k 90k 57k 29k 2018 2019 2020 2021 2022 2023 2024E Markets 2 4 7 11 17 25 32 PCPs 0.8k 1.0k 1.2k 1.4k 1.6k 2.2k 2.7k+ Copyrigh
Slide 48: Continued Momentum with Health Systems
Continued Momentum with Health Systems 2023 2024 • Largest integrated system in Northern New England • 1,700 employed and affiliated physicians • Comprehensive senior care services & established population health infrastructure • Generating early success in partnership Validates Ability to Penetrate
Slide 49: Dayton, Ohio: Successfully Unlocking Local TAM
Dayton, Ohio Case Study Successfully Unlocking Local TAM agilon Serving 39k Medicare Lives in a Small Market 4 Payer Dayton Market Context Payer 1 3k 39k MA Lives Total Care Model Medicare 15 PCPs Lives Size of MA 2020 165 PCPs population penetration 2024 935k 55% (up from 48% in 2019) + 3 Payer ACO
Slide 50: Western Michigan: Successfully Unlocking Local TAM
Western Michigan Case Study Successfully Unlocking Local TAM agilon Serving >40k Medicare Lives in a Large Geography Early in its Lifecycle 440k Medicare Lives Western MI Market Context Remaining Local TAM 4 Payer Payer 1 29k 13k MA Lives MA Lives 90 PCPs Total Care Model 50 PCPs Size of MA 2022 202
Slide 51: Significantly Expanding Local Market Opportunity
Significantly Expanding Local Market Opportunity Remaining In-Market TAM – Total PCPs Remaining In-Market TAM – (Based Year of Geography Go-Live) Total Medicare Eligibles (Based Year of Geography Go-Live) 33K 10.5M 26K 9% 8.0M Member-weighted 3Y MA CAGR across markets 4.7M 14K 12K 3.7M 8K 2.5M 5K 1.
Slide 52: Early Lifecycle Growth Enhances Long-term Visibility
Early Lifecycle Growth Enhances Long-term Visibility >80% of 2026 Membership are in Markets Already on the Platform Today 850K 750K (previously stated target) Members in class of ’25+ markets 550K Members in class of ’24 and earlier markets Larger market classes in ‘23/’24 increases confidence in FY
Slide 53: Financial Outlook
Financial Outlook Tim Bensley Chief Financial Officer Copyright © 2023 agilon health
Slide 54: Key Themes
Key Themes Adjusted EBITDA High Confidence in Strong Returns on Inflecting Long Term Outlook Capital and Balance Sheet Position Copyright © 2023 agilon health 54
Slide 55: agilon health Economic Model & Key Attributes
agilon health Economic Model & Key Attributes Illustrative Economic Model Key Attributes ~$900 PMPM Long-Term • 20-year joint venture partnerships Partnership • Shared economics with PCP partners High • Recurring per member revenue Visibility • 12+ Month Visibility to New Members ~$150-200+ PMPM (Ma
Slide 56: Significant Forward Momentum, Adjusted EBITDA Inflecting
Significant Forward Momentum, Adjusted EBITDA Inflecting Revenue Medical Margin Adjusted EBITDA $535M- $75M- >$5,500M $90M $560M $4,280- $4,370M ~60% $305M CAGR $4M >50% $2,708M CAGR $1,834M $182M $1,218M ($32)M $794M ($39)M $54M $63M $475M ($57)M 2018 2019 2020 2021 2022 2023G 2024P 2018 2019 2021
Slide 57: Drivers of Adjusted EBITDA Inflection and 2026 Outlook
Drivers of Adjusted EBITDA Inflection and 2026 Outlook 1 2 3 4 Members on Medical Margin Membership Operating Leverage Platform Progression by Vintage at Market and Markets and (Time on Platform) Corporate Member Cohorts Membership Adds Consistent Progression Stronger Growth in 2023- Significant Flo
Slide 58: Membership Growth is Accelerating Earlier Than We Expected
Membership Growth is Accelerating Earlier Than We Expected 1 Markets Member Additions Members 32 Medicare Advantage (MA) Medicare Advantage (MA) ~170K ~670K Direct Contracting/ACO REACH Direct Contracting/ACO REACH 25 ~135K 145K ~490K ~60% 122K CAGR 107K 17 360K ~50% CAGR 11 84K 238K 550K 8 405K 41K
Slide 59: Consistent Medical Margin Progression Across Member Cohorts
Consistent Medical Margin Progression Across Member Cohorts 2 Medical Margin PMPM by Member Cohorts 2018 Members 2019 Members 2020 Members 2021 Members 2022 Members $228 $209 $205 $170 $164 $145 $133 $133 $138 $96 $116 $97 $85 ~50% of Medical Margin $37 Reinvested Into Local $45 Primary Care 2018 20
Slide 60: Consistent Medical Margin Progression Across Market Classes
Consistent Medical Margin Progression Across Market Classes 2 Medical Margin PMPM by Market Class Membership CAGR by Market Class Class of 2018 Class of 2019 Class of 2020 Class of 2021 Class of 2022 Class of 2023 2018: 11% $201 $204 2020: 14% $200 2019: 23% $142 $146 $143 $148 2021: 11% $132 $123 $
Slide 61: Early Lifecycle Growth Improves Membership Vintage by 2026
Early Lifecycle Growth Improves Membership Vintage by 2026 – More Members in Mature Markets 3 Membership by Market Class Weighted Average Market Vintage Non-Partner Partner Year 2+ Partner Year 1 4.7 4.1 3.5 3.3 3.3 3.1 2.6 33% 52% 2.1 60% 87% 64% 84% 62% 70% 2019 2020 2021 2022 2023P 2024P 2025P 20
Slide 62: Medical Margin will Continue to Build
Medical Margin will Continue to Build Medical Margin Drivers Building to 2026 Medical Margin • Addressing PCP Variability Mature Partner Markets: 2018-2022 Classes • Executing Clinical Programs 40% of membership in 2026 $200-225 Medical Margin PMPM, 7 Year Avg. Market Vintage • Leveraging Partner Sc
Slide 63: Significant Operating Leverage at Market Level
Significant Operating Leverage at Market Level 4 Partner Market Operating Leverage Incremental Margin for Year 2+ Partners in 2022 (10 Markets) 2021 Medical Margin for Year 2+ Partners 2022 Medical Margin for Year 2+ Partners 80% flow-through to 40% flow-through to agilon $90M Partnership $72M +56%
Slide 64: Significant Momentum & Forward Visibility
Significant Momentum & Forward Visibility Membership Outlook and Build to 2026 ~970K DC/REACH Medicare Advantage ~670K ~850K ~490K 360K ~550K 238K ~405K 270K 186K 2021 2022 2023P 2024P 2026P Med. Margin (PMPM) $83 $96 $114-$117 ~$168 Medical Margin ($M) $182M $305M $535M-$560M ~$1,675M Platform Supp
Slide 65: Highly Attractive LTV/CAC
Highly Attractive LTV/CAC Payback Period <1 Year for 2021 and 2022 Member Cohorts Membership Medical Network Capital & Acquisition Costs Margin (PMPY) Contribution (PMPY) Return $1,749 $875 ~83K Members $1,433 $716 $1,020 2022 58K New Geography $510 25K Same Geography Payback: Year 1 Member LTV / CA
Slide 66: Balance Sheet Capital Deployment
Balance Sheet Capital Deployment Expect to Generate Positive Cash from Operations in 2024 Balance Sheet & Cash Flow ~$900M of cash as of Dec 31, Anticipate significant cash flow Independent of external funding adjusted EBITDA positive in generation 2024+ for achieving growth 2022 Capital Deployment
Slide 67: Summary
Summary Adjusted EBITDA Inflecting High Confidence in Attractive Returns on Capital Long Term Outlook and Balance Sheet Position Copyright © 2023 agilon health 67
Slide 68: Closing Remarks
Closing Remarks Steven Sell Chief Executive Officer Copyright © 2023 agilon health
Slide 69: Convergence of Factors Driving Success
Convergence of Factors Driving Success The Flywheel is Turning Faster Model Driving Consistent, Scaled Outcome Consistent improvement in access, quality and cost Invest More in PCPs Join Care Delivery agilon Network Accelerating Growth 145K total MA member additions in 2024, adding more members earl
Slide 70: Appendix
Appendix Copyright © 2023 agilon health 70
Slide 71: Non-GAAP Reconciliations
Non-GAAP Reconciliations ADJUSTED EBITDA (Dollars in thousands) Year Ended December 31, 2022 2021 2020 2019 2018 Net income (loss) $(106,864) $(406,787) $(60,052) (282,588) (146,926) (Income) loss from discontinued operations, net of income taxes (465) 1,303 (3,156) 168,285 65,338 Interest expense 4